BACKGROUND: High-quality external validation studies have recently been highlighted to be of paramount importance for proper translation of prognostic markers into the clinical setting. To that end, the authors examined associations of the insulin-like growth factor-II mRNA binding protein, IMP3, with clinical and pathologic features of clear cell renal cell carcinoma (ccRCC) in an independent cohort of patients to validate recent work showing IMP3 as a prognostic marker for RCC progression and death. METHODS: The authors studied 716 consecutive tumor specimens from patients treated with surgery at the study institution for unilateral, sporadic, noncystic ccRCC between 1990 and 1999. Tissues were stained and scored for IMP3 expression and these expression levels were correlated with clinical and pathologic features as well as clinical outcomes including progression to distant metastases and death from RCC. RESULTS: It was observed that 213 ccRCC specimens (29.8%) expressed tumor cell IMP3. IMP3 expression was associated with advanced stage and grade of primary tumors as well as other adverse features including coagulative tumor necrosis and sarcomatoid differentiation. After multivariate adjustment for ccRCC prognostic features, positive IMP3 expression was still found to be associated with a 42% increase in the risk of death from RCC (hazards ratio [HR], 1.42; P= .024). Among the subset of patients with clinically localized disease, positive IMP3 expression was associated with a nearly 5-fold increased risk of distant metastases (HR, 4.71; P< .001). CONCLUSIONS: Using a large and independent cohort of ccRCC patients, the authors confirmed that tumor cell IMP3 expression represents an independent predictor of aggressive ccRCC tumor behavior.
BACKGROUND: High-quality external validation studies have recently been highlighted to be of paramount importance for proper translation of prognostic markers into the clinical setting. To that end, the authors examined associations of the insulin-like growth factor-II mRNA binding protein, IMP3, with clinical and pathologic features of clear cell renal cell carcinoma (ccRCC) in an independent cohort of patients to validate recent work showing IMP3 as a prognostic marker for RCC progression and death. METHODS: The authors studied 716 consecutive tumor specimens from patients treated with surgery at the study institution for unilateral, sporadic, noncystic ccRCC between 1990 and 1999. Tissues were stained and scored for IMP3 expression and these expression levels were correlated with clinical and pathologic features as well as clinical outcomes including progression to distant metastases and death from RCC. RESULTS: It was observed that 213 ccRCC specimens (29.8%) expressed tumor cell IMP3. IMP3 expression was associated with advanced stage and grade of primary tumors as well as other adverse features including coagulative tumor necrosis and sarcomatoid differentiation. After multivariate adjustment for ccRCC prognostic features, positive IMP3 expression was still found to be associated with a 42% increase in the risk of death from RCC (hazards ratio [HR], 1.42; P= .024). Among the subset of patients with clinically localized disease, positive IMP3 expression was associated with a nearly 5-fold increased risk of distant metastases (HR, 4.71; P< .001). CONCLUSIONS: Using a large and independent cohort of ccRCC patients, the authors confirmed that tumor cell IMP3 expression represents an independent predictor of aggressive ccRCC tumor behavior.
Authors: Amy E Krambeck; R Houston Thompson; Haidong Dong; Christine M Lohse; Eugene S Park; Susan M Kuntz; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon Journal: Proc Natl Acad Sci U S A Date: 2006-06-23 Impact factor: 11.205
Authors: Zhong Jiang; Peigou G Chu; Bruce A Woda; Kenneth L Rock; Qin Liu; Chung-Cheng Hsieh; Cuizhen Li; Wengang Chen; Hai Ou Duan; Scott McDougal; Chin-Lee Wu Journal: Lancet Oncol Date: 2006-07 Impact factor: 41.316
Authors: R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon Journal: Proc Natl Acad Sci U S A Date: 2004-11-29 Impact factor: 11.205
Authors: Luigi Schips; Richard Zigeuner; Manfred Ratschek; Peter Rehak; Josef Rüschoff; Cord Langner Journal: Am J Clin Pathol Date: 2004-12 Impact factor: 2.493
Authors: Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Matthew K Tollefson; R Houston Thompson; Yuri Sheinin; Christine M Lohse; John C Cheville; Bradley C Leibovich; Eugene D Kwon Journal: Cancer Date: 2007-08-15 Impact factor: 6.860
Authors: Amy E Krambeck; Haidong Dong; R Houston Thompson; Susan M Kuntz; Christine M Lohse; Bradley C Leibovich; Michael L Blute; Thomas J Sebo; John C Cheville; Alexander S Parker; Eugene D Kwon Journal: Clin Cancer Res Date: 2007-03-15 Impact factor: 12.531
Authors: Valerie N Barton; Andrew M Donson; Diane K Birks; Bette K Kleinschmidt-DeMasters; Michael H Handler; Nicholas K Foreman; Sarah Z Rush Journal: J Neuropathol Exp Neurol Date: 2013-05 Impact factor: 3.685
Authors: Jeanette E Eckel-Passow; Christine M Lohse; Yuri Sheinin; Paul L Crispen; Christopher J Krco; Eugene D Kwon Journal: Diagn Pathol Date: 2010-07-07 Impact factor: 2.644
Authors: David F Schaeffer; Daniel R Owen; Howard J Lim; Andrew K Buczkowski; Stephen W Chung; Charles H Scudamore; David G Huntsman; Sylvia S W Ng; David A Owen Journal: BMC Cancer Date: 2010-02-23 Impact factor: 4.430